Top Papers

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half ... 1998 2026 2007 2016 2.1k
  1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (1998)

Citation Paths

Find how Peter McLaughlin's papers are connected to another author through citations.

Rankless by CCL
2026